This is an aggregated industry headline. Read the full story at FierceBiotech →
Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer
Alnylam has partnered with the person who helped put the "T" in ChatGPT, paying $30 million to work with Jakob Uszkoreit's Inceptive Nucleics on artificial intelligence-enabled drug design.
By FierceBiotech
· Jun 4, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
The WeekFierceBiotech ↗
Jasper Therapeutics is being reborn via a merger with Nasdaq-listed immune-mediated disease biotech Kira Pharm…
The WeekBriefing
Veradermics' oral minoxidil exceeded expectations in Phase 2, sending shares near $130 and strengthening its c…